Association between SLCO1B1 polymorphism and methotrexate-induced hepatotoxicity: a systematic review and meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Ji Min | - |
dc.contributor.author | Choi, Kyung Hee | - |
dc.contributor.author | Lee, Hong Hyun | - |
dc.contributor.author | Gwak, Hye Sun | - |
dc.date.accessioned | 2022-04-29T02:40:04Z | - |
dc.date.available | 2022-04-29T02:40:04Z | - |
dc.date.created | 2022-04-29 | - |
dc.date.issued | 2022-01 | - |
dc.identifier.issn | 0959-4973 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/84132 | - |
dc.description.abstract | Reports on the association between the solute carrier organic anion transporter 1B1 (SLCO1B1) T521C polymorphism and methotrexate-induced hepatotoxicity in patients with malignancies are inconsistent. This meta-analysis evaluated the association between the SLCO1B1 T521C polymorphism and methotrexate-induced hepatotoxicity. We performed a systematic review of previous reports from the PubMed, Web of Science, and EMBASE databases, and a meta-analysis was conducted. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated to evaluate the effect of the SLCO1B1 T521C polymorphism on the occurrence of methotrexate-induced hepatotoxicity. In total, data from five studies including 465 patients were analyzed. Patients had received a high-dose methotrexate regimen (1-5 g/m(2)). The SLCO1B1 variant allele (C allele) carriers had a 1.9-fold higher risk of hepatotoxicity than wild-type homozygote carriers (TT; OR, 1.94; 95% CI, 1.14-3.31). This meta-analysis demonstrated that C allele carriers of the SLCO1B1 polymorphism had a higher risk of hepatotoxicity than patients with the TT genotype. The SLCO1B1 T521C polymorphism may be a useful predictor for methotrexate-induced hepatotoxicity in patients with malignancies. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.relation.isPartOf | ANTI-CANCER DRUGS | - |
dc.title | Association between SLCO1B1 polymorphism and methotrexate-induced hepatotoxicity: a systematic review and meta-analysis | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000780317000017 | - |
dc.identifier.doi | 10.1097/CAD.0000000000001125 | - |
dc.identifier.bibliographicCitation | ANTI-CANCER DRUGS, v.33, no.1, pp.75 - 79 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85122714434 | - |
dc.citation.endPage | 79 | - |
dc.citation.startPage | 75 | - |
dc.citation.title | ANTI-CANCER DRUGS | - |
dc.citation.volume | 33 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Choi, Kyung Hee | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | hepatotoxicity | - |
dc.subject.keywordAuthor | malignancies | - |
dc.subject.keywordAuthor | methotrexate | - |
dc.subject.keywordAuthor | T521C polymorphism | - |
dc.subject.keywordPlus | ACUTE LYMPHOBLASTIC-LEUKEMIA | - |
dc.subject.keywordPlus | TOXICITY | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | MECHANISM | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | GENES | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.